loading page

Lipoprotein (a) is an Upstream Mediator of Aortic Stenosis
  • +6
  • Ahmed Makhdoum,
  • Yasuhiro Kotani,
  • Ryuichi Morishita,
  • Rei Otsu,
  • Yoshiaki Taniyama,
  • Amine Mazine,
  • Hon Leong,
  • Subodh Verma,
  • Bobby Yanagawa
Ahmed Makhdoum
University of Toronto

Corresponding Author:ahmed.makhdoum88@gmail.com

Author Profile
Yasuhiro Kotani
Okayama University
Author Profile
Ryuichi Morishita
Osaka University
Author Profile
Rei Otsu
Osaka University
Author Profile
Yoshiaki Taniyama
Osaka University
Author Profile
Amine Mazine
University of Toronto
Author Profile
Hon Leong
University of Toronto
Author Profile
Subodh Verma
University of Toronto
Author Profile
Bobby Yanagawa
University of Toronto
Author Profile

Abstract

Background: A landmark genome-wide association study has linked mutations in the plasma lipoprotein complex lipoprotein(a) [Lp(a)] and aortic stenosis. We attempted to determine whether Lp(a) is a key upstream mediator of aortic stenosis. Methods: Male, Lp(a) transgenic (N=10) and control mice (N=10) were fed a high cholesterol diet for 6 weeks, then hearts were sectioned for histological analysis. Human stenosis (N=8) and non-stenotic (N=7) aortic valve leaflets were obtained intraoperatively and submitted for histologic and immunohistochemical analyses. All histological sections were semi-quantitatively graded in a blinded manner (0-3/3+ units). Results: Aortic valves from Lp(a) transgenic mice fed a high-cholesterol diet demonstrated significant aortic valve changes including fibrosis (2.0/4 vs 0.5/4), calcification (1.9.4 vs 0.1/4) units, angiogenesis (1.1/4 vs 0.3/4) and inflammatory infiltration (1.0 vs 0.1/4) compared with control aortic valves (all p<0.001). Human stenotic aortic valve leaflets expressed greater Lp(a) (2.4/4 vs 1.7/4) in areas of fibrosis, inflammatory infiltration and angiogenesis, compared with non-stenotic aortic valve leaflets (p=<0.005) Conclusion: Our proof-of-concept studies offer evidence for a potential causative role of Lp(a) as a trigger of aortic stenosis. Further work is needed to confirm these results. Therapeutic strategies targeting Lp(a) levels may serve as a novel strategy to limit progressive calcification in aortic stenosis.